Investors / United States / Forepont Capital Partners
Forepont Capital Partners
Venture capital · New York, NY, United States · North America
Forepont Capital Partners is a venture capital firm established in 2017 in New York, with offices in New York, Palo Alto, London, Paris and Dubai. It invests in early-stage companies and typically retains a board position in its portfolio companies.
Invests inHealthcare & Biotech
In its own wordsbrain aineuroscienceartificial intelligencebiotechnologynanotechnologyhealthcare
Your fit with Forepont Capital Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsForepont Capital Partners lists 12 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (85%), AI & Machine Learning (8%) and Enterprise Software (8%). 50% of its companies are based in France. It invests most often alongside PL Neuro, 2050 Capital and ARCH Venture Partners.
Counts come from funding rounds that name Forepont Capital Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Forepont Capital Partners' whole history. Rounds on record name 1 company; its own site lists 12. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 30th | 12 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 94th | 85% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| PL Neuro | 2 |
| 2050 Capital | 1 |
| ARCH Venture Partners | 1 |
| ARK Venture Fund | 1 |
| Alven | 1 |
| Armyn Capital | 1 |
| Australia Venture Capital | 1 |
| Axial Partners | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers12100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 85% | 15% |
| AI & Machine Learning | 8% | 18% |
| Enterprise Software | 8% | 8% |
Co-investor network
who it backs companies with, and who they back togetherCompare Forepont Capital Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
12 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alterdiag develops and distributes rapid diagnostic tests to meet unmet medical needs | Healthcare & Biotech | Portfolio page | ||
| Ansella Therapeutics is a specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes. | Healthcare & Biotech | Portfolio page | ||
| Basecamp Vascular is a MedTech company developing active mechatronic technologies for endovascular navigation | Healthcare & Biotech | Portfolio page | ||
| Bay Bridge Digital integrates cloud solutions and provides advisory and integration services for businesses | AI & Machine LearningEnterprise Software | Portfolio page | ||
| The company develops and provides apps that use AI-driven assessments to monitor neurological clinical progress from home | Healthcare & Biotech | Portfolio page | ||
| BioSpeedia develops and manufactures in vitro diagnostics rapid test kits and ELISA kits for medical professionals and clinical diagnostic markets worldwide. | Healthcare & Biotech | Portfolio page | ||
| Blackrock Neurotech develops neurotechnology that improves patients' lives, particularly those with paralysis and other neurological disorders. | Healthcare & Biotech | Portfolio page | ||
| Enquyst Technologies is a biotechnology company that is disrupting the way that biological drugs are manufactured. | Healthcare & Biotech | Portfolio page | ||
| GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world’s most important bacterial pathogens. | Healthcare & Biotech | Portfolio page | ||
| Okeiro transforms the monitoring of transplanted patients and those with chronic diseases using predictive algorithms validated for care and clinical research. | Healthcare & Biotech | Portfolio page | ||
| Precision Neuroscience develops brain-computer interfaces to help people with paralysis operate digital devices using only their thoughts | Healthcare & Biotech | Portfolio page | ||
| Synchron builds implantable Brain-Computer Interfaces to protect what makes you human. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- forepont.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 21 Oct 2025
- Companies checked
- 12
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Forepont Capital Partners' profile as data
Pull Forepont Capital Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/forepont.com
# also
GET /v1/firms/forepont.com/portfolio
GET /v1/firms/forepont.com/coinvestors
GET /v1/firms/forepont.com/news